Santen Pharmaceutica (SNPHF) 46.1000 $SNPHF
Global Uveitis Therapeutics Pipeline Review 2014 - Analysis of 20 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6t3qv8/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Uveitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Alcon, Inc. - pSivida Corp. - Inovio Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - TheraKine Ltd. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - Regeneron Pharmaceuticals, Inc. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Clearside BioMedical, Inc. - AbbVie Inc. - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - voclosporin - fluocinolone acetonide - gevokizumab - sarilumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - Optiquel - interferon gamma-1b - ustekinumab - triamcinolone acetonide - VGX-1027 - HL-036 - PA-2612 - EBI-006 - ATX-UV2 - P-13 - IBI-70090 - EC-1669 - TNP-470 - PP-001 - EBI-028 - Col-Treg - ATX-UV1 - Narrow Spectrum Kinase Inhibitors - OPK-20018 - INV-17 For more information visit http://www.researchandmarkets.com/research/6t3qv8/uveitis
Global Macular Edema Therapeutics Pipeline Review 2014 - Key Analysis of 8 Companies & 11 Drug Profiles
M2 - Mon Apr 28, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/799c57/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Taiwan Liposome Company, Ltd. - Ampio Pharmaceuticals, Inc. - AlphaMab Co., Ltd Drug Profiles - ranibizumab - interferon beta-1a - betamethasone - beclomethasone dipropionate - trientine hydrochloride - dexamethasone SR - dexamethasone SR - PARP Inhibitors - DMI-5207 - PRM-167 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/79...ular_edema
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
Santen Phase III Study Meets Primary Endpoint for the Treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)
Business Wire - Fri Apr 04, 8:00AM CDT
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double-masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017
M2 - Thu Nov 21, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/384qp6/ophthalmology) has announced the addition of the "Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017" report to their offering. The ophthalmology drugs and devices market is divided into four major segments, namely, surgical devices, diagnostic and monitoring devices, vision care, and drugs. The devices market is divided into applications like surgery and diagnostics. Drugs market is classified into existing treatment drugs and drugs in pipeline and the vision care market is segmented into spectacles and contact lenses. The total market is forecasted till 2017. This market is also considered by formulation types such as capsules, gels, eye drops, ointment, and eye solutions. Advancements in technologies, high prevalence rates of refractive error, cataract, and glaucoma, increasing demand for the diagnostic procedures and low compliance with pharmaceuticals will propel the devices market. However, lack of awareness of diseases like glaucoma hinders the growth of this market. The drugs market will grow at a slower pace mainly due to the combined effect of loss of patent protection for several drugs and drying pipeline. The geographies covered in this study are North America, Europe, Asia-Pacific (APAC) and Rest of the world (RoW). North America is the largest market for ophthalmology drugs and devices, followed by Europe and Asia. North America and Europe is expected to grow at a slower pace, primarily due to the economic slowdown and saturation in these markets. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Ophthalmology Devices Market 5 Global Ophthalmology Drug Market 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles Companies Mentioned - Abbott Laboratories - Alcon, Inc. - Allergan, Inc - Bausch & Lomb, Inc. - Carl Zeiss Meditec Ag - Ellex Medical Lasers Limited - Essilor International S.A - Hoya Corporation - Iridex Corporation - Johnson & Johnson - Merck & Co., Inc - Nidek Co., Limited - Novagali Pharma S.A - Novartis Ag - Pfizer, Inc - Roche Holding Ag - Santen Pharmaceutical Co., Ltd. - Staar Surgical Company - Topcon Corporation - Ziemer Group Holding Ag For more information visit http://www.researchandmarkets.com/research/38...thalmology
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uveitis - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cbbpd2/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2013" report to their offering. 'Uveitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. Scope - A snapshot of the global therapeutic scenario for Uveitis. - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uveitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Uveitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. pSivida Corp. Inovio Biomedical Corporation Santen Pharmaceutical Co., Ltd. Apitope International NV Novartis AG Isotechnika Pharma Inc. TheraKine Inc. Enzo Biochem, Inc. Can-Fite BioPharma Ltd. Regeneron Pharmaceuticals, Inc. XOMA Ltd. Hanall Pharmaceutical Co., Ltd. Artielle ImmunoTherapeutics, Inc. ProtAffin Biotechnologie AG Endocyte, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/cbbpd2/uveitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid
Ocular Hypertension - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hswq4v/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Ocular Hypertension. - A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ocular Hypertension pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Ocular Hypertension Overview Therapeutics Development An Overview of Pipeline Products for Ocular Hypertension Companies Involved in Ocular Hypertension Therapeutics Development Ocular Hypertension - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Aerie Pharmaceuticals, Inc - Alcon, Inc - Allergan, Inc - Asahi Kasei Pharma - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd - Inotek Pharmaceuticals Corporation - Kowa Company, Ltd - LABORATOIRES THEA - Novagali Pharma SA - Ono Pharmaceutical Co - QLT Inc - Santen Incorporated - Santen Pharmaceutical Co., Ltd - Senju Pharmaceutical Co - Sun Pharmaceutical Industries Limited - Sylentis For more information visit http://www.researchandmarkets.com/research/hswq4v/ocular
Allergic Conjunctivitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bx8lxr/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Allergic Conjunctivitis. - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Allergic Conjunctivitis Overview Therapeutics Development An Overview of Pipeline Products for Allergic Conjunctivitis Allergic Conjunctivitis Therapeutics under Development by Companies Allergic Conjunctivitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Allergic Conjunctivitis Therapeutics - Products under Development by Companies Allergic Conjunctivitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Allergic Conjunctivitis Therapeutics Development Bausch & Lomb Incorporated Allergan, Inc. Bayer HealthCare AG Santen Pharmaceutical Co., Ltd Sun Pharmaceutical Industries Limited Fovea Pharmaceuticals SA LABORATOIRES THEA Oxagen Limited Morria Biopharmaceuticals Plc Drug Profiles Allergic Conjunctivitis Therapeutics - Drug Profile Updates Allergic Conjunctivitis Therapeutics - Discontinued Products Allergic Conjunctivitis Therapeutics - Dormant Products Allergic Conjunctivitis - Product Development Milestones Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/bx8lxr/allergic
Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o
Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
GlobeNewswire - Fri Apr 26, 6:01AM CDT
Santen Pharmaceutical Co., Ltd. (the "Company"
announces that at a meeting held today, its Board of Directors resolved to discontinue and abolish the "Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)" of the Company as of the close of the annual general meeting of the shareholders for the 101st fiscal year to be held on June 25, 2013 (the "Annual General Meeting of the Shareholders" , which were introduced based on the approval of the shareholders at the annual general meeting of the shareholders held on June 26, 2007, and partially revised and approved to be continued at the annual general meeting of the shareholders held on June 23, 2010 (the revised plan shall be referred to as the "Plan" . The Plan will remain effective until the close of the Annual General Meeting of the Shareholders.
Santen Ltd. Announces Change in Management Structure for U.S. Subsidiary Organization
Business Wire - Tue Mar 12, 8:00AM CDT
Santen Pharmaceutical Co., Ltd., (Osaka, Japan, Tokyo Stock Exchange: 4536) Japan's leading ophthalmic pharmaceutical company, announced today the appointment of Naveed Shams, M.D., Ph.D. as the President and CEO of Santen Inc., and Chief Scientific Officer of Santen Ltd. Prior to this new appointment, Dr. Shams was Vice President and Head of Global Clinical Development and Medical Affairs (GCD&MA). Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. in Microbiology & Immunology from the University of South Carolina. After completing a fellowship in Cornea and External Disease at the Schepens Eye Research Institute & Department of Ophthalmology, Harvard Medical School, he served on the Research Faculty in the Department. Dr. Shams joined Santen Inc. almost 3 years ago. His industry experience spans 19 years across multiple therapeutic areas and includes tenures with Genen
Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease
Business Wire - Thu Jan 31, 7:00AM CST
Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases. Santen will join with other investors to fund an additional $7.9 million for continued development of CLS1001 into pivotal testing and to further Clearside Biomedical's pipeline in ocular choroidal neovascularization and inflammatory diseases of the posterior segment. Santen, along with new investor Mountain Group Capital and its affiliates join current investors Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund.
Global Uveitis Therapeutics Pipeline Review 2014 - Analysis of 20 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6t3qv8/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Uveitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Alcon, Inc. - pSivida Corp. - Inovio Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - TheraKine Ltd. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - Regeneron Pharmaceuticals, Inc. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Clearside BioMedical, Inc. - AbbVie Inc. - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - voclosporin - fluocinolone acetonide - gevokizumab - sarilumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - Optiquel - interferon gamma-1b - ustekinumab - triamcinolone acetonide - VGX-1027 - HL-036 - PA-2612 - EBI-006 - ATX-UV2 - P-13 - IBI-70090 - EC-1669 - TNP-470 - PP-001 - EBI-028 - Col-Treg - ATX-UV1 - Narrow Spectrum Kinase Inhibitors - OPK-20018 - INV-17 For more information visit http://www.researchandmarkets.com/research/6t3qv8/uveitis
Global Macular Edema Therapeutics Pipeline Review 2014 - Key Analysis of 8 Companies & 11 Drug Profiles
M2 - Mon Apr 28, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/799c57/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Taiwan Liposome Company, Ltd. - Ampio Pharmaceuticals, Inc. - AlphaMab Co., Ltd Drug Profiles - ranibizumab - interferon beta-1a - betamethasone - beclomethasone dipropionate - trientine hydrochloride - dexamethasone SR - dexamethasone SR - PARP Inhibitors - DMI-5207 - PRM-167 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/79...ular_edema
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
Santen Phase III Study Meets Primary Endpoint for the Treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)
Business Wire - Fri Apr 04, 8:00AM CDT
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double-masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017
M2 - Thu Nov 21, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/384qp6/ophthalmology) has announced the addition of the "Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017" report to their offering. The ophthalmology drugs and devices market is divided into four major segments, namely, surgical devices, diagnostic and monitoring devices, vision care, and drugs. The devices market is divided into applications like surgery and diagnostics. Drugs market is classified into existing treatment drugs and drugs in pipeline and the vision care market is segmented into spectacles and contact lenses. The total market is forecasted till 2017. This market is also considered by formulation types such as capsules, gels, eye drops, ointment, and eye solutions. Advancements in technologies, high prevalence rates of refractive error, cataract, and glaucoma, increasing demand for the diagnostic procedures and low compliance with pharmaceuticals will propel the devices market. However, lack of awareness of diseases like glaucoma hinders the growth of this market. The drugs market will grow at a slower pace mainly due to the combined effect of loss of patent protection for several drugs and drying pipeline. The geographies covered in this study are North America, Europe, Asia-Pacific (APAC) and Rest of the world (RoW). North America is the largest market for ophthalmology drugs and devices, followed by Europe and Asia. North America and Europe is expected to grow at a slower pace, primarily due to the economic slowdown and saturation in these markets. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Ophthalmology Devices Market 5 Global Ophthalmology Drug Market 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles Companies Mentioned - Abbott Laboratories - Alcon, Inc. - Allergan, Inc - Bausch & Lomb, Inc. - Carl Zeiss Meditec Ag - Ellex Medical Lasers Limited - Essilor International S.A - Hoya Corporation - Iridex Corporation - Johnson & Johnson - Merck & Co., Inc - Nidek Co., Limited - Novagali Pharma S.A - Novartis Ag - Pfizer, Inc - Roche Holding Ag - Santen Pharmaceutical Co., Ltd. - Staar Surgical Company - Topcon Corporation - Ziemer Group Holding Ag For more information visit http://www.researchandmarkets.com/research/38...thalmology
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uveitis - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cbbpd2/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2013" report to their offering. 'Uveitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. Scope - A snapshot of the global therapeutic scenario for Uveitis. - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uveitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Uveitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. pSivida Corp. Inovio Biomedical Corporation Santen Pharmaceutical Co., Ltd. Apitope International NV Novartis AG Isotechnika Pharma Inc. TheraKine Inc. Enzo Biochem, Inc. Can-Fite BioPharma Ltd. Regeneron Pharmaceuticals, Inc. XOMA Ltd. Hanall Pharmaceutical Co., Ltd. Artielle ImmunoTherapeutics, Inc. ProtAffin Biotechnologie AG Endocyte, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/cbbpd2/uveitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid
Ocular Hypertension - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hswq4v/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Ocular Hypertension. - A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ocular Hypertension pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Ocular Hypertension Overview Therapeutics Development An Overview of Pipeline Products for Ocular Hypertension Companies Involved in Ocular Hypertension Therapeutics Development Ocular Hypertension - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Aerie Pharmaceuticals, Inc - Alcon, Inc - Allergan, Inc - Asahi Kasei Pharma - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd - Inotek Pharmaceuticals Corporation - Kowa Company, Ltd - LABORATOIRES THEA - Novagali Pharma SA - Ono Pharmaceutical Co - QLT Inc - Santen Incorporated - Santen Pharmaceutical Co., Ltd - Senju Pharmaceutical Co - Sun Pharmaceutical Industries Limited - Sylentis For more information visit http://www.researchandmarkets.com/research/hswq4v/ocular
Allergic Conjunctivitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bx8lxr/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Allergic Conjunctivitis. - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Allergic Conjunctivitis Overview Therapeutics Development An Overview of Pipeline Products for Allergic Conjunctivitis Allergic Conjunctivitis Therapeutics under Development by Companies Allergic Conjunctivitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Allergic Conjunctivitis Therapeutics - Products under Development by Companies Allergic Conjunctivitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Allergic Conjunctivitis Therapeutics Development Bausch & Lomb Incorporated Allergan, Inc. Bayer HealthCare AG Santen Pharmaceutical Co., Ltd Sun Pharmaceutical Industries Limited Fovea Pharmaceuticals SA LABORATOIRES THEA Oxagen Limited Morria Biopharmaceuticals Plc Drug Profiles Allergic Conjunctivitis Therapeutics - Drug Profile Updates Allergic Conjunctivitis Therapeutics - Discontinued Products Allergic Conjunctivitis Therapeutics - Dormant Products Allergic Conjunctivitis - Product Development Milestones Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/bx8lxr/allergic
Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o
Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
GlobeNewswire - Fri Apr 26, 6:01AM CDT
Santen Pharmaceutical Co., Ltd. (the "Company"
announces that at a meeting held today, its Board of Directors resolved to discontinue and abolish the "Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)" of the Company as of the close of the annual general meeting of the shareholders for the 101st fiscal year to be held on June 25, 2013 (the "Annual General Meeting of the Shareholders" , which were introduced based on the approval of the shareholders at the annual general meeting of the shareholders held on June 26, 2007, and partially revised and approved to be continued at the annual general meeting of the shareholders held on June 23, 2010 (the revised plan shall be referred to as the "Plan" . The Plan will remain effective until the close of the Annual General Meeting of the Shareholders. Santen Ltd. Announces Change in Management Structure for U.S. Subsidiary Organization
Business Wire - Tue Mar 12, 8:00AM CDT
Santen Pharmaceutical Co., Ltd., (Osaka, Japan, Tokyo Stock Exchange: 4536) Japan's leading ophthalmic pharmaceutical company, announced today the appointment of Naveed Shams, M.D., Ph.D. as the President and CEO of Santen Inc., and Chief Scientific Officer of Santen Ltd. Prior to this new appointment, Dr. Shams was Vice President and Head of Global Clinical Development and Medical Affairs (GCD&MA). Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. in Microbiology & Immunology from the University of South Carolina. After completing a fellowship in Cornea and External Disease at the Schepens Eye Research Institute & Department of Ophthalmology, Harvard Medical School, he served on the Research Faculty in the Department. Dr. Shams joined Santen Inc. almost 3 years ago. His industry experience spans 19 years across multiple therapeutic areas and includes tenures with Genen
Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease
Business Wire - Thu Jan 31, 7:00AM CST
Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases. Santen will join with other investors to fund an additional $7.9 million for continued development of CLS1001 into pivotal testing and to further Clearside Biomedical's pipeline in ocular choroidal neovascularization and inflammatory diseases of the posterior segment. Santen, along with new investor Mountain Group Capital and its affiliates join current investors Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund.
